Alendronate Sodium Tablet
Product Images NDC 64980-340

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 64980-340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alendronate Fig1)

The text describes the cumulative incidence of hip fractures in a three-year study involving patients with radiographic vertebral fracture at baseline. The incidence is represented as a percentage and plotted over time in months, with separate lines for the placebo and alendronate sodium treatments.*

FDA Label Image

Package Label-principal Display Panel (70 mg Blister Carton (4 Unit-of-use))

The text is a label of a medication named "Rising® NDC 64080-342-14" which is "Once Weekly Alendronate Sodium Tablets, USP". The pharmacist is instructed to dispense the medication guide to the patient and there are four tablets in the packaging. It also includes space for a prescription label to be applied.*

FDA Label Image

Figure 2 (Alendronate Fig2)

This text represents the results of the osteoporosis treatment studies in postmenopausal women, specifically the increase in BMD (Bone Mineral Density) after taking Alendronate 10 mg/day for three years. The results show a mean increase of 12% in BMD, relative to Placebo, at the lumbar spine. The femoral neck and trochanter also saw increases in BMD, but the specific percentages are not available due to the text being cut off.*

FDA Label Image

Figure 3 (Alendronate Fig3)

This is a chart presenting results from a study that evaluated the effect of Alendronate 10 mg/day versus a placebo on postmenopausal women with osteoporosis. The chart shows the mean percentage change from baseline in the lumbar spine bone mineral density (BMD) over a period of 36 months. The study was multinational and the results show that the group receiving Alendronate 10 mg/day had a higher BMD compared to the placebo group.*

FDA Label Image

Figure 4 (Alendronate Fig4)

FDA Label Image

Figure 5 (Alendronate Fig5)

FDA Label Image

Figure 6 (Alendronate Fig6)

The text is providing data on the effect of Alendronate 40 mg/day on serum alkaline phosphatase in comparison to Placebo or Etidronate 400 mg/day in studies of Paget’s Disease of Bone. The data is presented in a chart showing the mean % change from baseline over a period of 6 months with 0, 3, and 6 months marked on the horizontal axis. There are separate results for a multinational study and a U.S. study, with sample sizes of 27 and 41 respectively.*

FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablets Bottle))

FDA Label Image

Package Label-principal Display Panel (10 mg (100 Tablets Bottle))

FDA Label Image

Package Label-principal Display Panel (35 mg Blister Carton (4 Unit-of-use))

Rising® NDG 64080.341 14 is a medication containing Alendronate Sodium in tablet form, which is taken once every week. The pharmacist is advised to provide the patient with a medication guide. The rest of the text is not-readable and contains errors.*

FDA Label Image

Chemical Structure (Alendronate Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.